Alnylam Pharmaceuticals Stock (NASDAQ: ALNY)

Dernières nouvelles pour Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock

Alnylam Pharmaceuticals

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Alnylam Pharmaceuticals, Inc. - Common Stock

Alnylam Pharmaceuticals Inc

ALNYLAM PHARMACEUTICALS ORD

Shares of Exelixis, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/exel#NASDAQ">EXEL</a>) have risen 20.7% in the past three months compared with the industry&#39;s growth of 6.3%. The stock has also outperformed the sector and the S&amp;P 500 Index.
Exelixis has been a consistent outperformer in the year so far on the back of the strong performance of its lead drug Cabometyx and encouraging pipeline progress.
<h2>EXEL Outperforms Industry, Sector &amp; S&amp;P 500</h2>
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/9a/80573.jpg?v=2113034342" style="height:310px; width:600px" />
Image Source: Zacks Investment Research
<h2>Cabometyx Boosts EXEL</h2>
Cabometyx maintained its status as the leading tyrosine kinase inhibitor (TKI) for the treatment of renal cell carcinoma (RCC) in 2023. This was mainly attributable to its use in combination with Bristol Myers&#39;&nbsp;Opdivo in the first-line setting. The drug also maintained growth in the hepatocellular carcinoma indication.
BMY&#39;s Opdivo is one of the leading immuno-oncology drugs, approved for various oncology indications.
Management is also focused on the label expansion of Cabometyx. The FDA accepted EXEL&#39;s supplemental new drug application (sNDA) for cabozantinib for patients with previously treated advanced pancreatic neuroendocrine tumors (pNET) and those with previously treated advanced extra-pancreatic NET (epNET). The FDA assigned a standard review with a target action date of April 3, 2025. The FDA also granted the orphan drug designation to cabozantinib for the treatment of pNET.
A potential label expansion should further propel its growth prospects.
Exelixis also intends to submit an sNDA with the FDA later this year for cabozantinib, in combination with Tecentriq (atezolizumab), for metastatic castration-resistant prostate cancer.
<h2>EXEL Makes Encouraging Pipeline Progress</h2>
The pipeline progress has been impressive as well, as Exelixis looks to expand its oncology portfolio beyond Cabometyx.
Other promising candidates in Exelixis&#39; pipeline zanzalintinib, a next-generation oral TKI and XL309. In the first half of 2025, Exelixis intends to initiate a phase III study, STELLAR-311, to evaluate zanzalintinib compared with everolimus as a first oral therapy in patients with pNET and epNET.
The company also plans to advance phase I efforts for XL309 and XB010.
EXEL decided to discontinue the development of XB002. It plans to reallocate resources to new pivotal trials with zanzalintinib, advancing XL309 and its growing pipeline.
The successful development of additional drugs should broaden its portfolio and reduce its dependence on its lead drug, Cabometyx.
<h2>Exelixis&#39; Efforts to Boost Shareholder Value</h2>
Exelixis is also making efforts to increase shareholder value through repurchases.&nbsp; At the end of the second quarter, Exelixis completed its 2024 share repurchase program, having repurchased 20.3 million shares of the company&#39;s common stock for a total of $450 million.
Consequently, the company returned $1 billion to shareholders since the initial $550 million stock repurchase program was authorized in March 2023.
The board of directors has authorized the repurchase of up to an additional $500 million of the company&#39;s common stock through the end of 2025.
<h2>Valuation &amp; Estimates</h2>
Going by the price/sales ratio, EXEL&#39;s shares currently trade at 3.64x forward sales, higher than its mean of 3.34x and the biotech industry&#39;s 1.79x.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/42/80575.jpg?v=206418566" style="height:310px; width:600px" />
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2024 earnings per share has increased to $1.83 from $1.79 over the past 30 days.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/37/80578.jpg?v=1325426803" style="height:310px; width:600px" />
Image Source: Zacks Investment Research
<h2>Conclusion</h2>
Large biotech companies are generally considered safe havens for investors interested in this sector. EXEL is a good stock to buy now, with good fundamentals and growth prospects.
The stock has performed well this year. Potential label expansion of Cabometyx should boost its growth. The company&#39;s efforts to expand its portfolio are encouraging as well. The successful development of additional drugs should broaden its portfolio and reduce its dependence on its lead drug, Cabometyx.
<h2>Zacks Rank &amp; Other Key Picks</h2>
EXEL currently carries a Zacks Rank #2 (Buy).&nbsp;
Some other top-ranked stocks in the biotech sector are Alnylam Pharmaceuticals (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alny#NASDAQ">ALNY</a>) and Krystal Biotech (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/krys#NASDAQ">KRYS</a>), both carrying a Zacks Rank #1 (Strong Buy) at present.
ALNY&#39;s loss per share estimate for 2024 has narrowed from $1.20 to 63 cents in the past 60 days and the same for 2025 has narrowed from 34 cents to 27 cents.
Krystal Biotech&#39;s earnings per share for 2024 have increased to $2.38 from $1.98 in the past 90 days. Shares of KRYS have surged 42.8% year to date.
<a href="https://www.zacks.com/stock/news/2346907/exelixis-gains-20-7-in-three-months-is-this-the-right-time-to-buy?cid=CS-BENZ-FT-analyst_blog|rank_focused-2346907">To read this article on Zacks.com click here.</a>

Biotech

Earnings

Large Cap

Mid Cap

News

Management

Markets

Analyst Ratings

Trading Ideas

General

ALNY

EXEL

KRYS

Exelixis Gains 20.7% in Three Months: Is This the Right Time to Buy?

These eleven large-cap stocks were the worst performers in the last week. Are they in your portfolio?
<ol>
<li>Humana Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) stock tumbled 24.89% after the company updated investors on the decline in Stars&#8217; performance for 2025 and how it <a href="https://www.benzinga.com//node/41140319" target="_blank" rel="noreferrer noopener">will impact quality bonus payments in 2026</a>. Several analysts lowered <a href="https://www.benzinga.com/quote/hum/analyst-ratings" target="_blank" rel="noreferrer noopener">the stock&#8217;s price forecast</a>.</li>
<li>Stellantis N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STLA#NYSE">STLA</a>) stock fell 17.06% last week after Chrysler Parent&#8217;s U.S. sales nosedived 20% <a href="https://www.benzinga.com//node/41147560" target="_blank" rel="noreferrer noopener">in the third quarter</a>. <a href="https://www.benzinga.com//node/41190669" target="_blank" rel="noreferrer noopener">Several</a> analysts <a href="https://www.benzinga.com/quote/stla/analyst-ratings" target="_blank" rel="noreferrer noopener">downgraded the stock</a>.</li>
<li>Coinbase Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) shares dipped 10.63%. The company announced it will restrict services tied to Stablecoins that do not <a href="https://www.benzinga.com//node/41171878" target="_blank" rel="noreferrer noopener">meet MICA European regulations</a>.</li>
<li>Mobileye Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBLY#NASDAQ">MBLY</a>) shares were down 10.15%.</li>
<li>Rivian Automotive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) shares fell 10% last week after the company <a href="https://www.benzinga.com//node/41182921" target="_blank" rel="noreferrer noopener">lowered its annual production</a> guidance due to a supply shortage of shared components on the R1 and RCV platforms.</li>
<li>First Solar, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLSR#NASDAQ">FLSR</a>) stock lost 9.63% last week.</li>
<li>ConAgra Brands, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAG#NYSE">CAG</a>) stock declined 9.12% after the company reported <a href="https://www.benzinga.com//node/41140181" target="_blank" rel="noreferrer noopener">worse-than-expected Q1 financial results</a>.</li>
<li>Floor &amp; Decor Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FND#NYSE">FND</a>) stock declined 8.81% last week.</li>
<li>Summit Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) shares plummeted 8.59%. The company announced the completion of enrollment in its Phase III <a href="https://www.benzinga.com//node/41174110" target="_blank" rel="noreferrer noopener">HARMONi trial in 2L+ EGFRm NSCLC</a>.</li>
<li>Moderna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) stock fell 8.44%. The company <a href="https://www.benzinga.com//node/41169029" target="_blank" rel="noreferrer noopener">reached a stipulation</a> in its ongoing patent infringement litigation with Alnylam Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>).</li>
<li>Nike, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) stock fell 8.04% after multiple firms cut their respective price targets <a href="https://www.benzinga.com//node/41147332" target="_blank" rel="noreferrer noopener">following a first-quarter revenue miss</a>.</li>
</ol>
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41198527/us-listed-chinese-stocks-dominate-another-week-li-auto-jd-com-among-top-10-large-cap-gainers-last-we" target="_blank" rel="noreferrer noopener">US Listed Chinese Stocks Dominate Another Week &#8211; Li Auto, JD.com Among Top 10 Large Cap Gainers Last Week (Sept 30-Oct 4): Are The Others In Your Portfolio?</a></li>
</ul>
Photo by rafapress via Shutterstock

Movers

COIN

FLSR

MBLY

MRNA

RIVN

SMMT

STLA

Coinbase, Nike And Moderna Are Among Top 11 Large Cap Losers Last Week (Sept 30-Oct 4): Are The Others In Your Portfolio?

Alnylam Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) and Moderna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) have reached a stipulation in their ongoing <a target="_blank" href="https://www.benzinga.com/general/biotech/22/07/28082091/alnylam-hits-moderna-with-another-patent-infringement-suit-related-to-covid-19-vaccine" rel="noreferrer noopener">patent infringement litigation</a>.
In 2022, Alnylam filed a patent infringement lawsuit against Moderna, claiming it violated a&nbsp;<a target="_blank" href="https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&amp;Sect2=HITOFF&amp;d=PALL&amp;p=1&amp;u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&amp;r=1&amp;f=G&amp;l=50&amp;s1=11,382,979.PN.&amp;OS=PN/11,382,979&amp;RS=PN/11,382,979" rel="noreferrer noopener">newly obtained patent</a>.
The claim is over mRNA technology Moderna used in developing its COVID-19 vaccine, Alnylam says.&nbsp;
In the <a href="https://fingfx.thomsonreuters.com/gfx/legaldocs/znvneabarpl/IP%20ALNYLAM%20PATENTS%20moderna2.pdf" target="_blank" rel="noreferrer noopener">lawsuits filed</a> in U.S. District Court in Delaware, Alnylam said its newly granted patent covers the vaccine&#8217;s messenger-RNA delivery systems and violates an Alnylam patent on lipid nanoparticle (LNP) technology for delivering genetic material into human cells. 
However, after the court interpreted specific claim terms, Alnylam <a target="_blank" href="https://fingfx.thomsonreuters.com/gfx/legaldocs/gkplbmzqkpb/MODERNA%20ALNYLAM%20LAWSUIT%20dismissal.pdf" rel="noreferrer noopener">conceded</a> that the formulation of Moderna&#8217;s accused products does not infringe upon its asserted patent claims.
The case, brought by Alnylam, alleged that Moderna&#8217;s products violated their patent rights, leading Moderna to assert affirmative defenses and counterclaims for declaratory judgments of non-infringement and invalidity.
The court has jurisdiction over the claim and counterclaims, guided by U.S. patent laws.
Based on the court&#8217;s claim construction, Alnylam acknowledged it couldn&#8217;t secure a favorable judgment regarding the accused products&#8217; infringement of its patents.
The final stipulation allows for the entry of judgment in favor of Moderna, confirming that its currently formulated products do not infringe on Alnylam&#8217;s patents.
Both parties have agreed to dismiss the counterclaims and affirmative defenses raised by Moderna without prejudice, leaving the door open for further legal action if necessary in the future.
The stipulation is also without prejudice to either party&#8217;s rights in case of an appeal or remand, providing flexibility for potential developments.
In 2023, a U.S. appeals court affirmed a decision to cancel an Arbutus Biopharma Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABUS#NASDAQ">ABUS</a>) patent related to a legal fight over Moderna&#8217;s <a href="https://www.benzinga.com/general/biotech/23/04/31769282/us-court-favors-moderna-in-covid-19-vaccine-patent-infringement-case-with-arbutus-biopharma" target="_blank" rel="noreferrer noopener">COVID-19 vaccine</a>.
Price Action: ALNY stock is down 0.38% at $271.25, and MRNA stock is down 1.95% at $61.93 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/10/41166604/nano-cap-theriva-biologics-investigational-drug-for-transplant-related-complication-shows-safety-" target="_blank" rel="noreferrer noopener">Nano-Cap Theriva Biologics&#8217; Investigational Drug For Transplant-Related Complication Shows Safety In Bone Marrow Transplant Patients</a></li>
</ul>
Photo: Lutsenko_Oleksandr on Shutterstock

Health Care

Legal

ABUS

Alnylam's Concedes Its Patent Infringement Case Against Moderna's COVID-19 Vaccine

Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) has outperformed the market over the past 15 years by 6.55% on an annualized basis producing an average annual return of 18.47%. Currently, Alnylam Pharmaceuticals has a market capitalization of $35.41 billion. 
Buying $100 In ALNY: If an investor had bought $100 of ALNY stock 15 years ago, it would be worth $1,295.68 today based on a price of $275.85 for ALNY at the time of writing.
<h3>Alnylam Pharmaceuticals's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727708420_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 15 Years Ago, You Would Have $1,300 Today

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.alnylam.com%2F&amp;esheet=54128447&amp;newsitemid=20240929319308&amp;lan=en-US&amp;anchor=Alnylam+Pharmaceuticals%2C+Inc.&amp;index=1&amp;md5=17e1492493e56f6e52bc72686aedbaeb">Alnylam Pharmaceuticals, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>), the leading RNAi therapeutics company, today announced that two new data sets from the HELIOS-B Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM), were presented in the Late Breaking Clinical Research Session 1 at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2024, which was held virtually. An open access recording of Alnylam presentations will be available on the <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.hfsa.org&amp;esheet=54128447&amp;newsitemid=20240929319308&amp;lan=en-US&amp;anchor=HFSA+website&amp;index=2&amp;md5=c4b32eeeef2065535970d2a9d622d188">HFSA website</a> following the session.
Progression in ATTR-CM is associated with cardiac wall thickening, deterioration in systolic and diastolic function and increases in biomarkers of cardiac stress and injury, NT-pro-BNP and Troponin I.
"Consistent with demonstrated improvements in outcomes and health status, these new data show that vutrisiran attenuated measures of disease progression across multiple domains of cardiac structure and function, NT-proBNP and troponin I, in a contemporary ATTR-CM patient population," said Pushkal Garg, M.D., Chief Medical Officer, Alnylam. "These data demonstrate that rapid knockdown of TTR leads to an early impact on cardiac biomarkers and echocardiographic parameters, indicative of a potential disease-modifying effect, and underscores the benefit of treating patients with an RNAi therapeutic earlier in the course of disease. We remain confident that, with approval, vutrisiran has the potential to become a first-line therapy for ATTR amyloidosis with cardiomyopathy and are on track to complete multiple global regulatory submissions before the end of the year."
Analysis results
New echocardiographic data demonstrated that treatment with vutrisiran slowed disease progression in a contemporary population of patients with ATTR-CM across multiple domains of cardiac structure and diastolic and systolic function at Month 30 as compared to placebo. The magnitude of the treatment effects with vutrisiran compared to placebo were similar or greater in the monotherapy population. Significant improvements in both diastolic and systolic function were observed as early as 12 months and 18 months, respectively, in the overall population. The Month 30 results in the overall population are detailed in the table below.&#x2A;
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Overall population N=654</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Cardiac Wall Structure</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Mean Left Ventricular Wall Thickness Change from Baseline, cm LS Mean difference (Vutrisiran – Placebo)</td>
<td colspan="1" rowspan="1">-0.04 cm p=0.03</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Left Ventricular Mass Index Change from Baseline, g/m2 LS Mean difference (Vutrisiran – Placebo)</td>
<td colspan="1" rowspan="1">-10.6 g/m2 p=0.0047</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Left Ventricular Diastolic Function</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">E/A Ratio Change from Baseline LS Mean difference (Vutrisiran – Placebo)</td>
<td colspan="1" rowspan="1">-0.29 p=0.0434</td>
</tr>
<tr>
<td colspan="1" rowspan="1">E/e' Ratio Change from Baseline LS Mean difference (Vutrisiran – Placebo)</td>
<td colspan="1" rowspan="1">-1.82 p=0.00003</td>
</tr>
<tr>
<td colspan="1" rowspan="1">TDI Lateral e' Change from Baseline, cm/s LS Mean ± SEM</td>
<td colspan="1" rowspan="1">0.55 cm/s p=0.0005</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Left Ventricular Systolic Function</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Left Ventricular Ejection Fraction Change from Baseline, % LS Mean difference (Vutrisiran – Placebo)</td>
<td colspan="1" rowspan="1">2.03% p=0.02</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Absolute Global Longitudinal Strain Change from Baseline, % LS Mean difference (Vutrisiran – Placebo)</td>
<td colspan="1" rowspan="1">1.23% p=0.000002</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Left Ventricular Stroke Volume Change from Baseline, mL LS Mean difference (Vutrisiran – Placebo)</td>
<td colspan="1" rowspan="1">4.05 mL p=0.0007</td>
</tr>
</tbody>
</table>
</figure>
&#x2A;All p-values included within the table are nominal p-values.
In addition, analyses of cardiac biomarkers NT-proBNP and troponin I were also presented. At Month 30, the relative reduction in the fold change in NT-proBNP in patients treated with vutrisiran compared to placebo was 32% in the overall population and 43% in the monotherapy population (adjusted geometric mean fold change ratio [vutrisiran/placebo]: 0.68; nominal p-value 3.440E-12 and 0.57; nominal p-value 4.339E-12, respectively). At Month 30, relative reduction in the fold change of troponin I was 32% in the overall population and 45% in the monotherapy population (adjusted geometric mean fold change ratio [vutrisiran/placebo]: 0.68; nominal p-value 1.566E-14 and 0.55; nominal p-value 9.684E-17, respectively).
In the subgroup of patients receiving tafamidis at baseline, a relative reduction in the fold change of 18% was observed in NT-proBNP and 10% in troponin I (adjusted geometric mean fold change ratio [vutrisiran/placebo]: 0.82; nominal p-value 0.0045 and 0.90; nominal p-value 0.0849, respectively) at Month 30. For both NTproBNP and troponin I, patients treated with vutrisiran demonstrated nominally significant reductions relative to placebo at 6 months. These results were consistent across all pre-specified subgroups, with a larger treatment effect observed in the monotherapy population.
Detailed results from the HELIOS-B study were presented at the European Society of Cardiology annual congress on August 30, 2024, and simultaneously published in <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.nejm.org%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2409134&amp;esheet=54128447&amp;newsitemid=20240929319308&amp;lan=en-US&amp;anchor=The+New+England+Journal+of+Medicine&amp;index=3&amp;md5=6f6644c165dba8c02dae076071e6d87d">The New England Journal of Medicine</a>.
Alnylam plans to include a discussion of these data at its upcoming TTR Investor Day on Wednesday, October 9, 2024, at 8:30 am ET in New York City. The event will be webcast on the Investors section of the Company's website, <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.alnylam.com&amp;esheet=54128447&amp;newsitemid=20240929319308&amp;lan=en-US&amp;anchor=www.alnylam.com&amp;index=4&amp;md5=34c10ebf05396bb2b2457ed1bae44c65">www.alnylam.com</a>. A replay will be available on the Alnylam website within 48 hours after the event.

Reported Earlier, Alnylam's Vutrisiran Data Highlights Early Impact on Key Cardiac Biomarkers, Alnylam Eyes First-Line Therapy for ATTR Amyloidosis

Alnylam Pharmaceuticals's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NYSE">ALNY</a>) short percent of float has risen 18.05% since its last report. The company recently reported that it has 4.45 million shares sold short, which is 3.99% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.93 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Alnylam Pharmaceuticals Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727367321_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Alnylam Pharmaceuticals has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Alnylam Pharmaceuticals's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Alnylam Pharmaceuticals's peer group average for short interest as a percentage of float is 5.86%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Looking Into Alnylam Pharmaceuticals's Recent Short Interest

RBC Capital analyst Luca Issi reiterates Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Outperform and maintains $300 price target.

Price Target

Reiteration

RBC Capital Reiterates Outperform on Alnylam Pharmaceuticals, Maintains $300 Price Target

Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) has outperformed the market over the past 10 years by 3.01% on an annualized basis producing an average annual return of 13.61%. Currently, Alnylam Pharmaceuticals has a market capitalization of $32.89 billion. 
Buying $1000 In ALNY: If an investor had bought $1000 of ALNY stock 10 years ago, it would be worth $3,656.71 today based on a price of $256.21 for ALNY at the time of writing.
<h3>Alnylam Pharmaceuticals's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726075837_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 10 Years

Cantor Fitzgerald analyst Olivia Brayer reiterates Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Neutral and maintains $220 price target.

Cantor Fitzgerald Reiterates Neutral on Alnylam Pharmaceuticals, Maintains $220 Price Target

B of A Securities analyst Tazeen Ahmad maintains Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Buy and raises the price target from $295 to $307.

B of A Securities Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $307

Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alny#NASDAQ">ALNY</a>) were down 8.5% on Aug. 30, after the company announced detailed data from the phase III HELIOS-B, which evaluated its investigational RNAi therapeutic, Amvuttra (vutrisiran) for an expanded indication.
The HELIOS-B study is seeking to expand the label of Amvuttra for the treatment of transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy.
Per the company, the HELIOS-B study met the primary endpoint, demonstrating a statistically significant reduction in the composite of all-cause mortality and recurrent cardiovascular events in the overall population as well as the monotherapy population.
However, as a component of the primary endpoint, treatment with vutrisiran led to a 30% reduction in mortality in the monotherapy population in the double-blind period. Per management, this reduction was non-significant.
This might have hurt investors&#39; sentiments and resulted in the stock going down.
<h2>ALNY Stock Outperforming Industry</h2>
Shares of Alnylam have gained 37.3% so far this year compared with the industry&#39;s growth of 0.6%.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/42/76266.jpg?v=875498674" />
Image Source: Zacks Investment Research
Please note that vutrisiran is already approved in the United States for the treatment of adult patients with polyneuropathy of hereditary ATTR amyloidosis. This is also approved in the European Union for the same indication in adult patients with stage 1 or stage 2 polyneuropathy. Vutrisiran is marketed under the trade name Amvuttra in the United States and Europe.
In June 2024, Alnylam reported encouraging data from the phase III HELIOS-B study evaluating vutrisiran for the treatment of patients with ATTR amyloidosis with cardiomyopathy. Shares of the company soared on this news.
The phase III HELIOS-B study enrolled 655 adult patients with ATTR amyloidosis (hereditary or wild-type) with cardiomyopathy who were divided equally to receive vutrisiran 25mg or placebo subcutaneously once every three months for up to 36 months.
Alnylam is gearing up to proceed with global regulatory submissions, including filing a supplemental new drug application for vutrisiran with the FDA using a Priority Review Voucher later in 2024.
<h2>Amvuttra, a Key Revenue Driver for ALNY</h2>
Amvuttra is currently the top contributor to Alnylam&#39;s top line. This drug generated sales worth $425.4 million in the first half of 2024, increasing 82% year over year on a reported basis. The encouraging uptake of the drug is driven by new patients starting treatment as well as patients switching from ALNY&#39;s Onpattro(patisiran).
Onpattro is also approved in the United States and European Union to treat ATTR amyloidosis in adults.
If approved forthe new indication, Alnylam believes that vutrisiran has the potential to become the new standard of care for the treatment of ATTR amyloidosis with cardiomyopathy. This is likely to boost sales further and will expand the eligible patient population for the drug in future quarters.
<h2>Zacks Rank &amp; Stocks to Consider</h2>
Alnylam currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Illumina, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ilmn#NASDAQ">ILMN</a>), Krystal Biotech, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/krys#NASDAQ">KRYS</a>) and Fulcrum Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fulc#NASDAQ">FULC</a>), each sporting a Zacks Rank #1 (Strong Buy) at present.
In the past 60 days, estimates for Illumina&#39;s 2024 earnings per share have moved up from $1.18 to $3.62. Earnings per share estimates for 2025 have improved from $2.93 to $4.50. Year to date, shares of ILMN have lost 5.6%.
ILMN&#39;s earnings beat estimates in each of the trailing four quarters, the average surprise being 463.46%.
In the past 60 days, estimates for Krystal Biotech&#39;s 2024 earnings per share have increased from $1.98 to $2.38. Earnings per share estimates for 2025 have improved from $4.33 to $7.31. Year to date, shares of KRYS have risen 57.3%.
KRYS&#39; earnings beat estimates in three of the trailing four quarters while missing on the remaining occasion, the average surprise being 45.95%.
In the past 60 days, estimates for Fulcrum Therapeutics&#39; 2024 loss per share have narrowed from $1.24 to 48 cents. Loss per share estimates for 2025 have narrowed from $1.71 to $1.51. Year to date, shares of FULC have jumped 26.7%.
FULC&#39;s earnings beat estimates in each of the trailing four quarters, the average surprise being 393.18%.
<a href="https://www.zacks.com/stock/news/2330592/alny-down-despite-positive-data-from-heart-disease-drug-study?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2330592">To read this article on Zacks.com click here.</a>

Earnings Beats

Small Cap

FULC

ILMN

ALNY Down Despite Positive Data From Heart Disease Drug Study

<h3>Gainers</h3>
<ul>
<li>Theriva Biologics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/TOVX#AMEX">TOVX</a>) shares moved upwards by 34.2% to $6.31 during Monday's pre-market session. The market value of their outstanding shares is at $6.3 million. </li>
<li>Emergent BioSolutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) shares rose 17.62% to $10.48. The market value of their outstanding shares is at $549.1 million. </li>
<li>LogicMark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) stock moved upwards by 14.96% to $0.19. The market value of their outstanding shares is at $2.2 million. </li>
<li>Synaptogenix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNPX#NASDAQ">SNPX</a>) stock increased by 14.95% to $4.06. The market value of their outstanding shares is at $5.3 million. </li>
<li>Milestone Scientific (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MLSS#AMEX">MLSS</a>) shares moved upwards by 11.9% to $1.08. The market value of their outstanding shares is at $83.4 million. </li>
<li>Biomea Fusion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMEA#NASDAQ">BMEA</a>) shares moved upwards by 11.41% to $8.49. The company's market cap stands at $307.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>NuCana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) shares declined by 48.3% to $4.0 during Monday's pre-market session. The market value of their outstanding shares is at $9.0 million. </li>
<li>Catheter Precision (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VTAK#AMEX">VTAK</a>) shares declined by 27.95% to $0.98. </li>
<li>Ekso Bionics Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EKSO#NASDAQ">EKSO</a>) stock declined by 15.18% to $0.95. The company's market cap stands at $17.5 million. </li>
<li>Nutex Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUTX#NASDAQ">NUTX</a>) shares decreased by 7.69% to $20.18. The market value of their outstanding shares is at $102.2 million. </li>
<li>Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) shares fell 7.5% to $265.51. The market value of their outstanding shares is at $34.0 billion. </li>
<li>Exicure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>) shares declined by 6.42% to $1.75. The market value of their outstanding shares is at $3.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BMEA

EKSO

LGMK

MLSS

NCNA

NUTX

SNPX

TOVX

VTAK

XCUR

12 Health Care Stocks Moving In Monday's Pre-Market Session

Investors with a lot of money to spend have taken a bullish stance on Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ALNY, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 19 uncommon options trades for Alnylam Pharmaceuticals.
This isn't normal.
The overall sentiment of these big-money traders is split between 36% bullish and 31%, bearish.
Out of all of the special options we uncovered, 12 are puts, for a total amount of $1,479,365, and 7 are calls, for a total amount of $532,783.
<h3>Projected Price Targets</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $90.0 to $310.0 for Alnylam Pharmaceuticals over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for Alnylam Pharmaceuticals options trades today is 608.25 with a total volume of 5,819.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Alnylam Pharmaceuticals's big money trades within a strike price range of $90.0 to $310.0 over the last 30 days.
<h3>Alnylam Pharmaceuticals Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1725049066_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALNY</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$20.4</td>
<td>$18.2</td>
<td>$18.3</td>
<td>$260.00</td>
<td>$915.0K</td>
<td>70</td>
<td style="text-align: right;">500</td>
</tr>
<tr>
<td>ALNY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$177.5</td>
<td>$173.9</td>
<td>$173.9</td>
<td>$90.00</td>
<td>$173.9K</td>
<td>0</td>
<td style="text-align: right;">10</td>
</tr>
<tr>
<td>ALNY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/20/24</td>
<td>$14.8</td>
<td>$14.7</td>
<td>$14.7</td>
<td>$270.00</td>
<td>$151.4K</td>
<td>2.7K</td>
<td style="text-align: right;">323</td>
</tr>
<tr>
<td>ALNY</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$22.6</td>
<td>$19.5</td>
<td>$22.0</td>
<td>$280.00</td>
<td>$110.0K</td>
<td>412</td>
<td style="text-align: right;">88</td>
</tr>
<tr>
<td>ALNY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>10/18/24</td>
<td>$21.0</td>
<td>$19.5</td>
<td>$20.99</td>
<td>$250.00</td>
<td>$103.9K</td>
<td>0</td>
<td style="text-align: right;">57</td>
</tr>
</tbody>
</table>

<h3>About Alnylam Pharmaceuticals</h3>
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
<h3>Present Market Standing of Alnylam Pharmaceuticals</h3>
<ul>
<li>Currently trading with a volume of 3,753,765, the ALNY's price is down by -8.47%, now at $262.69. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 62 days.</li>
</ul>
<h3>What The Experts Say On Alnylam Pharmaceuticals</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $264.2.
<ul>
<li>Maintaining their stance, an analyst from Wells Fargo continues to hold a Equal-Weight rating for Alnylam Pharmaceuticals, targeting a price of $233. </li>
<li>An analyst from Needham persists with their Buy rating on Alnylam Pharmaceuticals, maintaining a target price of $320. </li>
<li>An analyst from Goldman Sachs has decided to maintain their Neutral rating on Alnylam Pharmaceuticals, which currently sits at a price target of $198. </li>
<li>An analyst from Raymond James has decided to maintain their Outperform rating on Alnylam Pharmaceuticals, which currently sits at a price target of $275. </li>
<li>An analyst from Barclays persists with their Overweight rating on Alnylam Pharmaceuticals, maintaining a target price of $295. </li>
</ul>
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Alnylam Pharmaceuticals with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Market Whales and Their Recent Bets on ALNY Options

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Buy and maintains $400 price target.

HC Wainwright & Co. Reiterates Buy on Alnylam Pharmaceuticals, Maintains $400 Price Target

Friday, Alnylam Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) stock is trading lower after the company shared detailed results from the HELIOS-B Phase 3 study of vutrisiran for ATTR amyloidosis with cardiomyopathy (ATTR-CM). Topline data was <a target="_blank" href="https://www.benzinga.com/general/biotech/24/06/39456940/alnylams-closely-watched-phase-3-heart-disease-trial-of-vutrisiran-hits-primary-endpoint-shares-s" rel="noreferrer noopener">revealed in June</a>.
The data were presented at the European Society of Cardiology Congress 2024.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/03/37491686/rochealnylam-blood-pressure-drug-aces-in-mid-stage-trial-analyst-says-zilebesiran-a" rel="noreferrer noopener">Roche/Alnylam Blood Pressure Drug Aces In Mid-Stage Trial, Analyst Says Zilebesiran As Promising Opportunity In Addressing Global Hypertension Challenges</a>.
In the overall population, vutrisiran reduced the risk of all-cause mortality and recurrent cardiovascular events by 28%, with similar reductions in the mortality and cardiovascular <a target="_blank" href="https://www.benzinga.com/pressreleases/24/08/b40647186/alnylam-presents-detailed-results-from-the-positive-helios-b-phase-3-study-of-vutrisiran-in-patien" rel="noreferrer noopener">events components of the endpoint</a>.
Mortality in this population was significantly reduced by 31% and by 36% up to 42 months.
In the monotherapy population, vutrisiran reduced the risk of all-cause mortality and recurrent cardiovascular events by 33% and reduced the risk of mortality by 35% up to 42 months.
A non-significant reduction of 30% in mortality was observed (nominal p-value 0.1179) in the monotherapy population.
Vutrisiran treatment was also associated with benefits versus placebo across multiple well-established clinical measures of disease progression.
At the ESC congress, Alnylam said that at month 30, patients on vutrisiran experienced a decline in 6-MWT of 26.46 meters from baseline, while 32.09 meters for the placebo arm.
Subgroup analyses of the primary and secondary endpoints demonstrated generally consistent results across all key patient segments, including patients receiving Pfizer Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) Vyndamax (tafamidis)&nbsp;at baseline.
In patients receiving baseline tafamidis, vutrisiran demonstrated a 22% reduction in the composite primary endpoint of ACM and recurrent CV events and a 41% reduction in ACM at 42 months versus placebo.
Trends toward greater than average benefit were seen in patients with baseline characteristics indicative of early disease.
The company remains on track to proceed with global regulatory submissions for vutrisiran starting later this year, including filing a supplemental New Drug Application with the FDA using a Priority Review Voucher.
BridgeBio Pharma Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBIO#NASDAQ">BBIO</a>) has ATTR-CM therapy acoramidis, currently&nbsp;under FDA priority review with an FDA action <a target="_blank" href="https://www.benzinga.com/pressreleases/24/02/g36930111/bridgebio-pharma-announces-u-s-food-and-drug-administration-fda-acceptance-of-new-drug-application" rel="noreferrer noopener">date of November 29</a>. BridgeBio Pharma stock jumped&nbsp;in reaction.
Price Action: ALNY stock is down 5.9% at $270.00 at last check Friday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/m-a/24/08/40650305/secureworks-stock-drops-as-dell-weighs-strategic-sale-options" target="_blank" rel="noreferrer noopener">SecureWorks Stock Drops as Dell Weighs Strategic Sale Options</a>.</li>
</ul>

Equities

BBIO

Alnylam Pharmaceuticals Stock Falls After Detailed Vutrisiran Data For A Condition With Stiff Heart Muscles

Alnylam Says Typo In Presentation Misstated Heart Drug Benefit

WIIM

Alnylam Pharmaceuticals shares are trading lower. The company announced results from its HELIOS-B Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis with cardiomyopathy.

Alnylam Presents Detailed Results From Positive HELIOS-B Phase 3 Study Of Vutrisiran: Achieved 28% Reduction In Primary Composite Of All-cause Mortality And Recurrent Cardiovascular Events, And 31% And 36% Reductions In All-cause Mortality

Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) has outperformed the market over the past 5 years by 13.34% on an annualized basis producing an average annual return of 27.24%. Currently, Alnylam Pharmaceuticals has a market capitalization of $34.55 billion. 
Buying $100 In ALNY: If an investor had bought $100 of ALNY stock 5 years ago, it would be worth $326.67 today based on a price of $269.14 for ALNY at the time of writing.
<h3>Alnylam Pharmaceuticals's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1724706021_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 5 Years Ago Would Be Worth $300 Today

Michael Ulz, an analyst from Morgan Stanley, maintained the Hold rating on Alnylam Pharma (ALNY – Research Report). The associated price target rem...

Alnylam Pharma's Promising Clinical Data Tempered by Market Factors in Hold Rating Assessment

Piper Sandler analyst Edward Tenthoff reiterated a Buy rating on Alnylam Pharma (ALNY – Research Report) today and set a price target of $296.00. T...

Piper Sandler Sticks to Their Buy Rating for Alnylam Pharma (ALNY)

In a report released today, Ritu Baral from TD Cowen maintained a Buy rating on Alnylam Pharma (ALNY – Research Report), with a price target of $28...

Alnylam Pharma (ALNY) Receives a Buy from TD Cowen

In a report released today, Liisa Bayko from Evercore ISI maintained a Buy rating on Alnylam Pharma (ALNY – Research Report), with a price target o...

Alnylam Pharma (ALNY) Gets a Buy from Evercore ISI

In a report released yesterday, Whitney Ijem from Canaccord Genuity maintained a Buy rating on Alnylam Pharma (ALNY – Research Report), with a pric...

Buy Rating Affirmed for Alnylam Pharma on Strong Phase 3 Trial Results and Favorable Sales Forecast

The biotech sector is booming, fueled by rising healthcare demands, exciting advancements in technology, and increased FDA drug approvals. Thus, investing in Illumina (ILMN), Alnylam Pharmaceuticals (ALNY), and Gilead Sciences (GILD) could be a golden opportunity for those looking to ride the wave of future breakthroughs. Read on… With rapid innovations in biotechnology, companies are developing groundbreaking therapies and diagnostic tools that address chronic diseases and improve patient outcomes. This continuous advancement is not only enhancing healthcare quality but also attracting attention from investors seeking to capitalize on the sector's transformative potential.
Amid this backdrop, fundamentally robust biotech stocks such as Illumina, Inc. (<a href="https://stocknews.com/stock/ILMN/">ILMN</a>), Alnylam Pharmaceuticals, Inc. (<a href="https://stocknews.com/stock/ALNY/">ALNY</a>), and Gilead Sciences, Inc. (<a href="https://stocknews.com/stock/GILD/">GILD</a>) could offer significant return potential owing to their pipelines that are awaiting FDA approvals.
The biotechnology industry is experiencing significant growth, driven by increasing demand for personalized medicine and breakthroughs in treating chronic diseases. The approval of new drugs by the Food and Drug Administration (FDA) has also played a crucial role in this expansion.
This year alone, the FDA has <a href="https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024">approved 30 novel drugs</a> targeting conditions ranging from lung cancer to Alzheimer's disease and various other chronic ailments.
A recent survey by GlobalData highlights this positive momentum, revealing that <a href="https://www.pharmaceutical-technology.com/analyst-comment/biotech-funding-optimism-rises/">44% of healthcare industry professionals</a> worldwide feel optimistic or extremely optimistic about the recovery of biotech funding in the upcoming twelve months. This sentiment reflects confidence in the sector's ability to innovate and meet rising healthcare demands.
Additionally, ongoing advancements and advanced diagnostics are propelling the biotechnology field forward. The transformative potential of Generative AI in drug discovery further amplifies this growth.
According to the McKinsey Global Institute, Generative AI could contribute <a href="https://www.mckinsey.com/industries/life-sciences/our-insights/early-adoption-of-generative-ai-in-commercial-life-sciences">up to $110 billion annually</a> in economic value for the pharmaceutical and medtech sectors, indicating a bright future for biotechnology.
Furthermore, as per a report by Precedence Research, the global biotechnology market is expected to expand at <a href="https://www.precedenceresearch.com/biotechnology-market#:~:text=The%20U.S.%20biotechnology%20market%20size,with%20revenue%20share%20in%202023.">a CAGR of 11.5%</a>, reaching approximately $4.61 trillion by 2034.
Considering these factors, let's discuss the fundamentals of three <a href="https://stocknews.com/category/biotech/">Biotech</a> stocks, starting with #3.
Stock #3: Illumina, Inc. (<a href="https://stocknews.com/stock/ILMN/">ILMN</a>)
ILMN provides sequencing- and array-based solutions for genetic and genomic analysis. It operates through two main segments: Core Illumina and GRAIL. The company is also engaged in a research collaboration, option, and license agreement which focuses on discovering novel dual tumor-associated antigens (TAA) that target trispecific antibodies.
On August 27, ILMN <a href="https://www.illumina.com/company/news-center/press-releases/press-release-details.html?newsid=cca694db-8cc7-4b6a-9449-38ccd9329816">received FDA approval</a> for its TruSight&#x2122; Oncology (TSO) Comprehensive test and two companion diagnostic (CDx) indications. The TSO Comprehensive test profiles over 500 genes in solid tumors, increasing the chance of identifying actionable biomarkers for targeted therapies or clinical trials.
The approval could strengthen ILMN's position in oncology diagnostics, likely driving higher demand for its products. The expanded market presence could positively impact its stock price as precision medicine grows.
In the fiscal 2024 second quarter that ended June 24, ILMN reported a total revenue of $1.11 billion with a gross margin of 64.8%. Its non-GAAP operating profit rose 2.4% from the year-ago value to $84 million. Plus, the company's non-GAAP net income and EPS came in at $57 million and $0.36, up 14% and 12.5% year-over-year, respectively.
ILMN's EPS for the fiscal 2024 third quarter, ending September 2024, is expected to grow 164.8% year-over-year to $0.87. Moreover, the company's EPS for the fiscal 2024 fourth quarter ending December 2024 is forecasted to rise by 573.7% from the prior year's period to $0.94.
In parallel, the company has surpassed the consensus revenue estimates in three of the trailing four quarters, which is impressive.
The stock has gained 21.2% over the past three months to close the last trading session at $131.20.
ILMN's <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> reflect its promising outlook. The stock has an overall rating of B, equating to a Buy in our proprietary rating system. The POWR Ratings assess stocks by 118 different factors, each with its own weighting.
ILMN has a B grade for Growth, Sentiment, and Quality. Within the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry, it is ranked #28 out of 333 stocks.
To see the other ILMN ratings for Value, Momentum, and Stability, <a href="https://stocknews.com/stock/ILMN/">click here</a>.
Stock #2: Alnylam Pharmaceuticals, Inc. (<a href="https://stocknews.com/stock/ALNY/">ALNY</a>)
ALNY focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases.
On August 30, ALNY <a href="https://investors.alnylam.com/press-release?id=28411">reported detailed results</a> from the Positive HELIOS-B Phase 3 Study of vutrisiran, an investigational RNAi therapeutic for ATTR amyloidosis with cardiomyopathy. The study showed significant improvements in all primary and secondary endpoints. Vutrisiran reduced all-cause mortality and recurrent cardiovascular events by 28%.
With mortality reduced by 31% during the double-blind period and 36% over 42 months, vutrisiran demonstrates strong potential in treating cardiomyopathy. As a key pipeline asset, its success positions ALNY for future market growth. This could strengthen ALNY's portfolio, driving revenue and enhancing investor confidence, which could positively impact its stock price.
On April 7, ALNY <a href="https://investors.alnylam.com/press-release?id=28111">announced positive results</a> from the KARDIA-2 Phase 2 study, which evaluated the efficacy and safety of a single subcutaneous dose of zilebesiran. Zilebesiran, added to standard antihypertensives like indapamide, amlodipine, or olmesartan, demonstrated promising outcomes, advancing its development as a potential treatment for hypertension.
As an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT), zilebesiran offers the possibility of biannual dosing. Its success in the pipeline could significantly benefit ALNY by providing a long-acting hypertension treatment, potentially expanding its market presence and driving long-term revenue growth.
During the fiscal 2024 second quarter that ended June 30, ALNY's net product revenues increased 34.1% year-over-year to $410.09 million. Its non-GAAP operating income came in at $137.90 million compared to an operating loss of $154.03 million in the previous year's quarter.
Furthermore, the company's non-GAAP <a href="https://www.investopedia.com/terms/n/netincome.asp">net income</a> amounted to $73.77 million or $0.56 per share, compared to a loss of $201.62 million or $1.62 per share recorded in the last year's period.
Analysts predict ALNY's revenue for the fiscal year ending December 2024 to increase 20.5% year-over-year to $2.20 billion. Moreover, the company's revenue for the next fiscal year ending December 2025 is estimated to rise 13.2% from the prior year to $2.49 billion. The company has surpassed the consensus revenue estimates in three of four trailing quarters.
ALNY's stock has surged 53% over the past nine months and 56% over the past year to close the last trading session at $273.88.
ALNY's bright prospects are mirrored in its POWR Ratings. The stock has an overall rating of B, equating to a Buy in our proprietary rating system.
ALNY has a B grade for Sentiment and Quality. It is ranked #27 among 333 stocks in the Biotech industry.
<a href="https://stocknews.com/stock/ALNY/">Click here</a> to access additional ALNY ratings (Growth, Value, Momentum, and Stability).
Stock #1: Gilead Sciences, Inc. (<a href="https://stocknews.com/stock/GILD/">GILD</a>)
GILD is a biopharmaceutical company dedicated to advancing treatments for life-threatening diseases such as human immunodeficiency virus (HIV), viral hepatitis, COVID-19, and cancer.  Its portfolio of marketed products includes Biktarvy, Genvoya, Odefsey, Truvada, Harvoni, Vemlidy, and Veklury, among others.
On September 12, GILD <a href="https://www.gilead.com/news/news-details/2024/gileads-twiceyearly-lenacapavir-for-hiv-prevention-reduced-hiv-infections-by-96-and-demonstrated-superiority-to-daily-truvada">shared interim analysis results</a> from a pivotal Phase 3 clinical trial for lenacapavir, its twice-yearly injectable HIV-1 capsid inhibitor. The results revealed a remarkable 96% reduction in HIV infections compared to background HIV incidence (bHIV), positioning lenacapavir as a potential game-changer in HIV treatment and enhancing GILD's reputation in the field.
Earlier, on August 14, GILD <a href="https://www.gilead.com/news/news-details/2024/gileads-livdelzi-seladelpar-granted-accelerated-approval-for-primary-biliary-cholangitis-by-us-fda">announced the FDA's accelerated approval</a> of Livdelzi&#xAE; (seladelpar) for treating primary biliary cholangitis (PBC). The treatment, in combination with ursodeoxycholic acid (UDCA), achieved a 25% normalization rate of alkaline phosphatase (ALP) values after 12 months.
This improvement indicates a significant reduction in liver-related complications, enhancing patient outcomes. Together, these developments strengthen GILD's pipeline, potentially driving substantial revenue growth and solidifying its position as a leader in innovative therapies.
For the fiscal 2024 second quarter, which ended on June 30, GILD's total revenues increased 5.4% year-over-year to $ 6.95 billion. The company's non-GAAP operating income came in at $3.27 billion, rising 43.4% from the previous year's quarter.
In addition, its non-GAAP net income attributable to GILD came in at $2.52 billion or $2.01 per share, up 49.2% and 50% year-over-year, respectively.
The consensus revenue and EPS estimates of $27.99 billion and $7.13 for the fiscal year ending December 2025 reflect a rise of 1% and 87.7% year-over-year, respectively. Also, the company has an excellent surprise history; it surpassed the consensus revenue estimates in all four trailing quarters.
GILD's stock has surged 6.8% over the past nine months and 10.7% over the past year to close the last trading session at $83.94.
It's no surprise that GILD has an overall A rating, equating to a Strong Buy in our POWR Ratings system.
GILD has an A grade for Value and a B for Quality. Within the same industry, it is ranked #5.
Beyond what is stated above, we've also rated GILD for Momentum, Stability, Growth, and Sentiment. Get all GILD ratings <a href="https://stocknews.com/stock/GILD/">here</a>.
What To Do Next?
Discover 10 widely held stocks that our proprietary model shows have tremendous downside potential. Please make sure none of these "death trap" stocks are lurking in your portfolio:
<a href="https://report.stocknews.com/free-report/10-stocks-to-sell/?formplacement=artbotad_10sell">10 Stocks to SELL NOW! &gt;</a>  

<hr />
GILD shares rose $0.37 (+0.44%) in premarket trading Monday. Year-to-date, GILD has gained 7.41%, versus a 20.49% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Aanchal Sugandh</h2> <img src='https:/wp-content/uploads/2022/12/Aanchal-Sugandh_Headshot.jpg' style="float:left; padding:5px;width:125px;">Aanchal's passion for financial markets drives her work as an investment analyst and journalist. She earned her bachelor's degree in finance and is pursuing the CFA program.

She is proficient at assessing the long-term prospects of stocks with her fundamental analysis skills. Her goal is to help investors build portfolios with sustainable returns.<a href="https://stocknews.com/authors/?author=aanchal-sugandh">More...</a>The post <a href=https://stocknews.com/news/gild-alny-ilmn-3-biotech-stocks-to-watch-as-fda-approvals-roll-in/>3 Biotech Stocks to Watch as FDA Approvals Roll In</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Biotech Stocks to Watch as FDA Approvals Roll In

Genomics is on the brink of revolutionizing healthcare with breakthroughs that could redefine treatment and diagnosis. As this field rapidly evolves, investing in fundamentally sound genomics stocks like Regeneron Pharmaceuticals (REGN), Alnylam Pharmaceuticals (ALNY), and Illumina (ILMN) could be beneficial. Read more… Over the past two decades, the cost of gene sequencing has plummeted, turning genomics into a cutting-edge field with enormous potential. Thanks to substantial investments and waves of research funding, the industry is making significant strides in understanding and treating a range of genetic disorders and complex diseases.
In this rapidly evolving landscape, fundamentally sound companies like Regeneron Pharmaceuticals, Inc. (<a href="https://stocknews.com/stock/REGN/">REGN</a>), Alnylam Pharmaceuticals, Inc. (<a href="https://stocknews.com/stock/ALNY/">ALNY</a>), and Illumina, Inc. (<a href="https://stocknews.com/stock/ILMN/">ILMN</a>) are at the forefront of transforming healthcare.
Genomics is not just about unlocking the secrets of DNA; it's about applying that knowledge to real-world medical treatments. By understanding the unique genetic code of individuals, doctors can now offer more precise diagnostics and personalized treatments for conditions that range from common cancers to rare genetic disorders. It's an approach that brings us closer to an era of truly personalized medicine, where your DNA guides your healthcare plan.
Sales of next-generation genomic medicines are expected to <a href="https://ascent.usbank.com/private-capital-management/ascent-resources-and-insights/investment-strategies/investing-in-genomics.html">hit $84 billion by 2028</a>, driven by successful clinical trials and the growing need for new treatments. Moreover, the global genomics market is projected to grow from $39.53 billion in 2024 to $157.47 billion by 2033 at a <a href="https://www.biospace.com/genomics-market-size-to-hit-usd-157-47-billion-by-2033#:~:text=The%20global%20genomics%20market%20size,period%20(2024%2D2033).">CAGR of 16.6%</a>.
Given these encouraging trends, let's look at the fundamentals of the top <a href="https://stocknews.com/category/biotech/">Biotech</a> stocks, beginning with the third choice.
Stock #3: Alnylam Pharmaceuticals, Inc. (<a href="https://stocknews.com/stock/ALNY/">ALNY</a>)
ALNY focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases.
On April 30, 2024, ALNY and Medison Pharma, a global pharma company focused on providing access to highly innovative therapies for patients in international markets, announced a further expansion of their existing partnership in Central &amp; Eastern Europe and Israel also to include selected markets in LATAM and APAC and additional international markets.
This partnership is expected to ensure that ALNY's commercial therapies are available across multiple international markets, thus enhancing their income streams.
ALNY's trailing-12-month gross profit and EBIT margins of 87% and 4.38% are 50.5% and 64.7% higher than their respective industry averages of 57.81% and 2.66%. Also, its trailing-12-month levered FCF margin of 18.10% compares to the industry average of 1.60%.
During the fiscal second quarter that ended June 30, 2024, ALNY's net product revenues increased 34.1% year-over-year to $410.09 million. Its non-GAAP operating income came in at $137.90 million versus a year-ago operating loss of $154.03 million. Also, the company's non-GAAP <a href="https://www.investopedia.com/terms/n/netincome.asp">net income</a> amounted to $73.77 million or $0.56 per share, compared to a loss of $201.62 million or $1.62 per share recorded last year.
Analysts predict ALNY's revenue for the current year (ending December 2024) to increase 20.5% year-over-year to $2.20 billion. Further, its revenues are expected to register a 13.2% growth from the prior year, settling at $2.49 billion. It is no surprise that the company has topped the consensus revenue estimates in three of the trailing four quarters.
Over the past six months, ALNY's stock has surged 85.3% to close the last trading session at $273.15.
ALNY's bright prospects are reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of B, equating to a Buy in our proprietary rating system. The POWR Ratings assess stocks by 118 different factors, each with its own weighting.
It has an A grade for Sentiment and a B for Quality. ALNY is ranked #28 among 335 stocks in the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry. <a href="https://stocknews.com/stock/ALNY/">Click here</a> to access additional ALNY ratings (Growth, Value, Momentum, and Stability).
Stock #2: Illumina, Inc. (<a href="https://stocknews.com/stock/ILMN/">ILMN</a>)
ILMN develops, manufactures, and markets life science tools and integrated systems for large-scale genetic variation and function analysis. It operates through the Core Illumina and GRAIL segments. It provides sequencing and array-based instruments and consumables, whole-genome sequencing, genotyping, NIPT, and product support services.
On July 9, the company acquired Fluent BioSciences, a company known for its advanced single-cell technology. This acquisition strengthens ILMN's multiomics growth strategy by offering its customers advanced capabilities in single-cell research and enabling them to provide more comprehensive solutions to their customers.
ILMN's trailing-12-month EBIT margin of 4.63% is 80% higher than the industry average of 2.57%. Likewise, its 14.34% trailing-12-month EBITDA margin is 132.7% above the industry average of 6.16%. Also, its trailing-12-month levered FCF margin of 19.39% compares to the industry average of 1.61%.
In the second quarter that ended June 30, 2024, ILMN reported a total revenue of $1.11 billion with a gross margin of 64.8%. Its non-GAAP operating profit rose 2.4% from the year-ago value to $84 million. The company's non-GAAP net income and EPS came in at $57 million and $0.36, up 14% and 12.5% year-over-year, respectively.
Street expects ILMN's EPS for the fiscal third quarter (ending September 2024) to increase 164.7% year-over-year to $0.87, while its revenue is forecasted to be $1.08 billion. Moreover, it surpassed the consensus revenue estimates in three of the trailing four quarters, which is impressive.
The stock has gained 21.2% over the past three months to close the last trading session at $130.97.
ILMN's POWR Ratings reflect this promising outlook. The stock has an overall rating of B, equating to a Buy in our proprietary rating system.
It also has a B grade for Growth, Sentiment, and Quality. Within the same industry, it is ranked #24. To see the other ILMN ratings for Value, Momentum, and Stability, <a href="https://stocknews.com/stock/ILMN/">click here</a>.
Stock #1: Regeneron Pharmaceuticals, Inc. (<a href="https://stocknews.com/stock/REGN/">REGN</a>)
REGN discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases. Its product portfolio includes EYLEA, Dupixent, Libtayo, Praluent, REGEN-COV, Kevzara solution, and ARCALYST, among other injections.
On September 13, the U.S. Food and Drug Administration (FDA) approved the use of Dupixent&#xAE; (dupilumab) as an add-on maintenance treatment for adolescent patients aged 12 to 17 years with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP). This approval expands the initial June 2019 FDA approval in CRSwNP for patients aged 18 years and older.
The stock's trailing-12-month EBITDA and levered FCF margins of 33.50% and 15.50% are considerably higher than the industry averages of 6.16% and 1.61%, respectively. Similarly, its trailing-12-month EBIT margin of 30.14% compares to the industry average of 2.57%.
REGN's net revenues for the second quarter (ended June 2024) increased 12% year-over-year to $3.55 billion. Its non-GAAP net income grew 14.3% from the year-ago value to $1.35 billion, while its income from operations stood at $1.07 billion, up 5.2% year-over-year. The company's non-GAAP net income per share came in at $11.56, representing a 12.9% year-over-year growth.
The consensus revenue estimate of $3.66 billion for the fiscal third quarter (ending September 2024) represents an 8.7% improvement year-over-year. The consensus EPS estimate of $11.76 for the ongoing quarter represents a 1.5% increase from the same period last year. The company has a promising earnings surprise history, as it surpassed the consensus EPS estimates in three of the trailing four quarters.
Shares of REGN have gained 38.1% over the past year and 29.7% year-to-date.
It is no surprise that REGN has an overall rating of A, equating to a Strong Buy in our POWR Ratings system. It has a B grade for Value and Quality. Out of 335 stocks in the same industry, it is ranked #8.
In addition to the POWR Rating grades I've just highlighted, you can see REGN's Growth, Momentum, Stability, and Sentiment ratings <a href="https://stocknews.com/stock/REGN/">here</a>.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
REGN shares were unchanged in premarket trading Thursday. Year-to-date, REGN has gained 29.66%, versus a 18.86% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Shweta Kumari</h2> <img src='https:/wp-content/uploads/2022/03/Shweta-Kumari_Image-2.jpg' style="float:left; padding:5px;width:125px;">Shweta's profound interest in financial research and quantitative analysis led her to pursue a career as an investment analyst. She uses her knowledge to help retail investors make educated investment decisions.<a href="https://stocknews.com/authors/?author=shweta-kumari">More...</a>The post <a href=https://stocknews.com/news/regn-alny-ilmn-3-genomics-stocks-transforming-healthcare/>3 Genomics Stocks Transforming Healthcare</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Genomics Stocks Transforming Healthcare

BridgeBio granted Perform rating at Oppenheimer on market challenges

GILD

REGN

Press Releases

Alnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period Activity

Alnylam Issues 2023 Corporate Responsibility Report

Alnylam Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Populations

Alnylam to Webcast Conference Call Discussing Second Quarter 2024 Financial Results

Alnylam Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Period Activity

Alnylam to Present Detailed Results from the HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress 2024

Alnylam to Webcast Presentations at Upcoming September Investor Conferences

Alnylam Presents Detailed Results from the Positive HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress

Alnylam to Webcast TTR Investor Day

Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024

Comments

Alnylam Pharmaceuticals

Actualités

Dernières nouvelles pour Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL